IPO News Archive

AVEO Pharmaceuticals prices IPO at $9, below the $13-$15 range

3/11/10


AVEO Pharmaceuticals, which is developing a Phase 3 renal cell carcinoma treatment similar to blockbuster Avastin, raised $81 million by selling 9 million shares at $9 after originally filing to raise $98 million by selling 7 million shares at a range of $13-$15. The Cambridge, MA-based biotech will list on the NASDAQ tomorrow under the symbol AVEO. J.P. Morgan and Morgan Stanley acted as the lead underwriters on the deal.

Keywords/Tickers: AVEO
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest